Stocktoria
Nuvation Bio Inc. NUVB
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2020-07-01
Nuvation Bio Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | 10.1% | — | — | — |
| Operating margin | -338.7% | -7527.3% | — | — | — |
| Net margin | -325.3% | -7213.8% | — | — | — |
| Return on assets | -34.4% | -105.1% | -12.2% | -15.5% | -11.2% |
| Return on equity | -66.9% | -122.5% | -12.5% | -15.9% | -11.6% |
| Debt / equity | 0.15× | — | — | — | — |
| Current ratio | 6.95 | 9.04 | 44.11 | 50.70 | 45.62 |
| Revenue growth | 699.0% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001811063 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.